Attached files
| file | filename |
|---|---|
| EX-31.1 - EX-31.1 - Applied Therapeutics Inc. | aplt-20191231ex311941c35.htm |
| EX-32.2 - EX-32.2 - Applied Therapeutics Inc. | aplt-20191231ex3226178db.htm |
| EX-32.1 - EX-32.1 - Applied Therapeutics Inc. | aplt-20191231ex32154614b.htm |
| EX-31.2 - EX-31.2 - Applied Therapeutics Inc. | aplt-20191231ex312973d3d.htm |
| EX-10.14 - EX-10.14 - Applied Therapeutics Inc. | aplt-20191231ex101452112.htm |
| EX-10.13 - EX-10.13 - Applied Therapeutics Inc. | aplt-20191231ex1013b9169.htm |
| EX-4.7 - EX-4.7 - Applied Therapeutics Inc. | aplt-20191231ex47f74bdd4.htm |
| 10-K - 10-K - Applied Therapeutics Inc. | aplt-20191231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in Registration Statement on Form S-8 (Form S-8 No. 333-231618) of our report dated March 13, 2020, with respect to the financial statements of Applied Therapeutics, Inc., included in this Annual Report on Form 10-K for the year ended December 31, 2019.
|
/s/ Ernst & Young LLP |
|
New York, New York |
|
March 13, 2020 |
|
|